Skip to navigation Skip to content

Diagnostic Workup


Diagnostic workup tools

Magnetic resonance imaging (MRI) in multiple sclerosis

The new 2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis is a revision to the 2018 CMSC protocol and guidelines. The recommendations were published to better inform MRI in MS clinical practice and include the following updates:
  • Translational research in MRI
  • Modifications to MRI acquisition to increase diagnostic accuracy, improve new lesion identification and monitor treatment
  • Additional guidance on the safe use of gadolinium-based contrast agents (GBCAs)
  • MRI use in certain populations (pediatric MS, during pregnancy and postpartum)
  • A focus on standardized MRI protocols and reporting

Gadolinium FDA drug safety communication

In 2018 the FDA Issued a Safety Communication and Safety Measures Related to a Commonly Used MRI Contrast Agent.  The FDA is evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for MRI.


Become a Research Champion

An MS Research Revolution

Support MS Research

Understanding and ending MS can’t come fast enough – it will take all of us working together. It’s easy to be a champion for MS Research – join us and proudly let everyone know that you’re helping to lead the MS Research Revolution.

Become a Research Champion

Become a Research Champion
© 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.